Institute of Pathology, University Hospital Cologne, 50937 Cologne, Germany.
Department of Pathology, Kameda Medical Center, Kamogawa 296-0041, Japan; Department of Pathology Informatics, Nagasaki University, Nagasaki 852-8131, Japan.
Cell Rep Med. 2024 Sep 17;5(9):101697. doi: 10.1016/j.xcrm.2024.101697. Epub 2024 Aug 22.
Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors. In this study, we develop a clinically useful computational pathology platform for NSCLC that can be a foundation for multiple downstream applications and provide immediate value for patient care optimization and individualization. We train the primary multi-class tissue segmentation algorithm on a substantial, high-quality, manually annotated dataset of whole-slide images with lung adenocarcinoma and squamous cell carcinomas. We investigate two downstream applications. NSCLC subtyping algorithm is trained and validated using a large, multi-institutional (n = 6), multi-scanner (n = 5), international cohort of NSCLC cases (slides/patients 4,097/1,527). Moreover, we develop four AI-derived, fully explainable, quantitative, prognostic parameters (based on tertiary lymphoid structure and necrosis assessment) and validate them for different clinical endpoints. The computational platform enables the high-precision, quantitative analysis of H&E-stained slides. The developed prognostic parameters facilitate robust and independent risk stratification of patients with NSCLC.
非小细胞肺癌(NSCLC)是最常见的恶性肿瘤之一。在这项研究中,我们开发了一个临床实用的 NSCLC 计算病理学平台,可为多个下游应用提供基础,并为优化和个体化患者护理提供即时价值。我们在一个具有大量高质量、手动注释的全切片图像数据集上训练主要的多类组织分割算法,该数据集包括肺腺癌和鳞状细胞癌。我们研究了两个下游应用。使用来自 NSCLC 病例的大型、多机构(n=6)、多扫描仪(n=5)、国际队列(切片/患者 4097/1527)训练和验证 NSCLC 亚型算法。此外,我们开发了四个基于人工智能的、完全可解释的、定量的、预后参数(基于三级淋巴结构和坏死评估),并验证了它们在不同临床终点的适用性。该计算平台能够实现对 H&E 染色切片的高精度、定量分析。开发的预后参数有助于对 NSCLC 患者进行稳健且独立的风险分层。